Short answer
Syndax Pharmaceuticals Inc (SNDX) filed an 8-K current report with the SEC on June 10, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders approved new 2026 equity plan effective June 10, 2026.
Syndax Pharmaceuticals Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Stockholders approved new 2026 equity plan effective June 10, 2026
- 2026 Plan reserves 7,200,000 shares, creating potential future dilution
- 2015 Omnibus Incentive Plan expired March 6, 2026, ending new awards under that plan
- Recycled shares from terminated 2015 Plan awards can replenish 2026 Plan availability
- New 2026 ESPP replaces the 2015 ESPP, with no 2015 ESPP share rollover
Item 5.07 · Submission of Matters to a Vote of Security Holders
- All director nominees elected; Michael Metzger received 58,113,110 votes, while Pierre Legault had 21,467,975 withheld
- Executive compensation approved with 55,688,039 votes for and 2,985,350 against
- Independent auditor ratified overwhelmingly with 66,603,912 votes for and 162,947 against
- 2026 Plan approved narrowly, with 33,333,263 votes for versus 25,392,051 against
- 2026 ESPP approved decisively with 58,661,941 votes for and 74,047 against
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Syndax Pharmaceuticals Inc 8-K filings
Get the next SNDX 8-K as it lands
Follow SNDX for push alerts, or ask the research agent what this filing means.